Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy (NCT07312682) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy
China202 participantsStarted 2024-12-09
Plain-language summary
This retrospective single-center study investigates whether four-dimensional CT (4DCT)-based lung ventilation imaging can guide functional lung avoidance radiotherapy (FLAR) for patients with primary lung cancer.
Ventilation maps generated from planning 4DCT are used to identify well-ventilated lung regions, enabling paired comparison between functional lung avoidance radiotherapy plans and conventional anatomic radiotherapy plans.
The study aims to assess whether incorporating functional lung information into radiotherapy planning can reduce radiation exposure to well-ventilated lung while maintaining adequate tumor coverage, and to explore its relationship with radiation-induced lung injury.
All analyses are based on existing clinical imaging, treatment planning data, and follow-up records. No additional interventions, imaging, or procedures are performed as part of this study.
Who can participate
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically confirmed primary lung cancer (adenocarcinoma, squamous cell carcinoma, or small-cell carcinoma) treated with thoracic radiotherapy.
* High-quality 4DCT scans performed before radiotherapy, enabling generation of ventilation or perfusion maps.
* Radiotherapy plans designed using IMRT.
* Availability of both functional lung avoidance plans and conventional anatomical radiotherapy plans for paired analysis.
* Complete treatment and follow-up records, including radiation-induced lung injury (e.g., radiation pneumonitis) and pulmonary function tests.
Exclusion Criteria:
* Incomplete or poor-quality imaging data preventing accurate ventilation/perfusion map generation.
* Radiotherapy interrupted or incomplete for any reason.
* Severe underlying lung diseases (e.g., extensive emphysema, pulmonary fibrosis, active tuberculosis) that may confound treatment outcomes or toxicity assessment.
* Presence of other untreated primary malignancies during the study period.
* Prior lung surgery or local therapies (e.g., ablation) that may affect evaluation of radiation-induced lung injury.
* Missing follow-up data, making assessment of radiation-induced lung injury or long-term lung function changes impossible.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Radiation-Induced Lung Injury (Grade ≥2)
Timeframe: Assessed at 3 months, 6 months, and 12 months after completion of radiotherapy.
Trial details
NCT IDNCT07312682
SponsorThe Second Affiliated Hospital of Chongqing Medical University